Keywords: Ligand Pharma, Spectrum Pharma, Captisol-enabled melphalan, Multiple myeloma, Financial guidance

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

Article | 14 March 2013

Ligand Pharmaceuticals (Nasdaq: LGND) has signed a global license and supply agreements with fellow US drugmaker Spectrum Pharmaceuticals (Nasdaq: SPPI) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Ligand Pharmaceuticals

Spectrum Pharmaceuticals

Go to company listing

Related Drugs

melphalan

Go to drug listing